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S U M M A R Y
Objective: Comparison of a fractional inactivated poliovirus vaccine (IPV) dose administered
intradermally (ID) to a full dose administered intramuscularly (IM).
Methods: Healthy Filipino infants were randomized to receive IPV as either a fractional (1/5th) dose ID by
needle injection or a full dose IM at 6, 10, and 14 weeks and a booster at 15–18 months of age. Pre- and
post-vaccination anti-polio 1, 2, and 3 titers were estimated. Adverse events were monitored throughout
the study.
Results: Following primary series vaccination, anti-polio 1, 2, and 3 titers were 8 (1/dil) in 99–100% of
participants, and the ID route was non-inferior to the IM route. Depending on the study group, antibody
persistence was detected in 83–100% of participants, and the booster dose resulted in a strong
anamnestic response in all groups. The incidence of adverse events in each group was similar, except for
injection-site erythema (higher in the ID group).
Conclusions: Primary series and booster vaccination of a fractional IPV dose administered by the ID route
was highly immunogenic and well tolerated. These data conﬁrm the medical validity of using fractional
ID doses of IPV. The programmatic feasibility of implementing affordable mass vaccination programs
based on this delivery mode has yet to be established.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The oral poliovirus vaccine (OPV) has been an important tool in
moving towards the World Health Organization (WHO) goal of
global eradication of poliomyelitis.1 However, its use is linked to
the occurrence of vaccine-associated paralytic poliomyelitis
(VAPP), with several recent outbreaks due to circulating virus-
derived polioviruses (cVDPV) having been identiﬁed in countries
using OPV.2,3 In 2007, the Advisory Committee on Polio Eradication
recommended that efforts should be made to develop affordable
inactivated poliovirus vaccine (IPV) as one of the alternatives
towards discontinuation of OPV that would be practical for use in
low-income settings.4 Currently, numerous cost-reduction
approaches are being promoted by the WHO and are being
evaluated, including reduction in the number of administrations
(reduced schedule), reduction in the antigen content by use of
adjuvants, and optimization of vaccine production processes or use
of poliovirus seed strains that are less infectious or not infectious at
all.5 In addition, intradermal delivery of a reduced dose of IPV is§ NLM registration numbers: NCT00604058 and NCT00885157.
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1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.10.002envisaged as a way to reduce the cost of the polio vaccine. While
such a dose-reduction approach has previously been validated in
terms of immunogenicity for numerous vaccines,6–8 its proof-of-
concept and programmatic feasibility in polio vaccination with
modern IPVs has not been fully established.
The ﬁrst reports of the immunogenicity of IPV administered
intradermally (ID) in adults and children were by Salk in 1953.9,10
Soon after the availability of the ﬁrst commercial IPVs in 1955,
several European and American vaccination programs relied for a
while on vaccinations with IPV administered ID by the Mantoux
technique (using a needle).11–17 Later, with the availability of the
modern IPV (the so-called enhanced-potency IPV), three separate
proof-of-concept studies were carried out in India in the 1990s, in
which a fractional dose of IPV administered by the ID route
demonstrated that one-ﬁfth of the intramuscular (IM) volume is
immunogenic when delivered ID with needles. None of these
studies, however, was randomized versus IM.18–20 ID administra-
tion by the Mantoux technique has several disadvantages,
including the inability to precisely determine the volume of the
administered vaccine due to leakage at the site of injection, the
necessity for training and skill, and the time needed to perform the
injection. The development and use of multi-use nozzle jet
injectors (MUNJIs) has been tainted by subject-to-subject blood-
borne contamination. Now the envisaged approach is to useses. Published by Elsevier Ltd. All rights reserved.
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ﬁlled syringes to be inserted in the injectors, or disposable syringes
that are inserted into the injector device for administration after
ﬁlling at the time of use from a vaccine vial presentation.21 Various
manufacturers are currently developing affordable DSJIs.
Recently, the WHO sponsored two studies in Cuba and in Oman
with two different IPV vaccines used with two different schedules
(6–10–14 weeks in Cuba and 2–4–6 months in Oman).22,23 The
vaccines were administered either ID using a DSJI ﬁlled at the time
of use (Biojector1 2000 (Bioject), customized for an ID adminis-
tration) or by IM route using a regular syringe and needle. The
primary objective of these WHO-sponsored studies was to
demonstrate non-inferiority in terms of seroconversion for the
ID route compared to the IM route. Although both studies
demonstrated clinically relevant immunogenicity of the vaccines
following ID administration, non-inferiority was not demonstrated
in the Cuban study. The overall response (seroconversion and
median titers) was lower for the 6–10–14 week schedule
compared to the 2–4–6 month schedule, and lower in the ID
groups compared to the IM groups.
To complete these recent investigations, we conducted a
randomized controlled trial in the Philippines to compare the
primary series and booster immunogenicity of IPV by ID
administration using the Mantoux technique to the IM route
when used with the most challenging (least immunogenic)
schedule (i.e. at 6–10–14 weeks of age – the Expanded Programme
on Immunization (EPI) schedule). The ID route remains unlicensed
as a route of administration for polio vaccine, and the primary
objective of the primary series part of our study was to assess the
non-inferiority of the fractional dose of IPV administered ID in
comparison to the full dose administered IM, in terms of
seroprotection (percentage of subjects with antibody titers 8
(1/dil)), using the non-inferiority deﬁnition used by most National
Regulatory Agencies (NRAs) for licensure purposes, deﬁned as the
lower limit of the two-tailed 95% conﬁdence interval (CI) of the
observed difference between the fractional ID group versus the full
dose IM group being <5 percentage points. The immunogenicity
endpoints for the booster part of the study were to check for
antibody persistence a year after the primary vaccination and to
describe the immunogenicity and safety of the booster dose
administered ID or IM. We also assessed the safety and
reactogenicity of IPV administration by both routes.
2. Materials and methods
2.1. Study design and participants
The primary series vaccination study was a randomized,
controlled, open-label, phase II study conducted at the University
of the East Ramon Magsaysay Memorial Medical Center, Manila,
Philippines. Healthy infants were randomized to receive either a
fractional (1/5th of the IM volume) dose of IPV by the ID route or a
full dose via the IM route, as per the EPI schedule at 6, 10, and 14
weeks of age. Participants were excluded either at the time of
screening (0 to 7 days after birth, at which time the study was
explained) or at the ﬁrst vaccination (6 weeks of age) if they had
illnesses or health issues (established by clinical examination and/
or medical history), which could have interfered with the study, or
a congenital or acquired immunodeﬁciency, or human immuno-
deﬁciency virus, hepatitis B antigen, or hepatitis C seropositivity.
Study participants who completed the primary vaccination
series and returned for the booster study then received the same
fractional ID or full IM dose of IPV as was received in the primary
series.
Study protocols for the primary series study and the booster
vaccination study were approved by the ethics committee at thestudy center and the studies were conducted in accordance with
the Edinburgh revision of the Declaration of Helsinki, Good Clinical
Practice (GCP), International Conference on Harmonisation (ICH)
guidelines and the European Directive 2001/20/EC for clinical
studies conducted outside the European Union. A signed informed
consent form was obtained from the parent or other legally
acceptable representative of each participant before any study
procedure was performed.
2.2. Study vaccines and administration
The IPV vaccine, IMOVAX1 Polio, batch numbers A0190-1 and
A0427-2 for the primary vaccination and batch numbers D0051-1
and B0281-5 for the booster vaccination, was manufactured and
supplied by Sanoﬁ Pasteur, Lyon, France. The vaccine for ID
administration was supplied as 5-ml vials, with each 0.1-ml dose
containing 8, 1.6, and 6.4 D antigen units of types 1, 2, and 3
poliovirus, respectively. The vaccine for IM administration was
supplied as 0.5-ml pre-ﬁlled syringes, with each dose containing
40, 8, and 32 D antigen units of types 1, 2, and 3 poliovirus,
respectively. The fractional dose was administered ID in the right
upper arm with a syringe mounted with a 13-mm 30-gauge needle,
and the full dose was administered IM in the anterolateral area of
the right thigh with a syringe equipped with a 16-mm 25-gauge
needle.
Concomitantly in the study, participants received, free of
charge, commercially available diphtheria–tetanus–whole-cell
pertussis–Haemophilus inﬂuenzae type b (DTwP–Hib; 2, 4, 6
months of age) and hepatitis B (0, 1, 6 months of age) vaccines
10 days before or after the IPV vaccination (not assessed as part of
our study).
2.3. Immunogenicity assessment
During the primary series vaccination, blood samples for the
immunogenicity assessments were collected just before the ﬁrst
dose and 1 month after the third dose. For the booster study, blood
samples were collected just before the booster dose and 1 month
later.
The seroneutralization assay to determine the anti-polio 1, 2,
and 3 antibody titers was conducted by Focus Diagnostics, Inc.24
This assay measures the viability of poliovirus-sensitive Vero cells
that are exposed to neutralizing antibodies in the serum sample
mixed with poliovirus strains 1, 2, and 3, which act as a challenge
virus. For this trial, wild-type poliovirus strains 1, 2, and 3
(Mahoney, MEF-1, and Saukett, respectively) were used instead of
the Sabin strains used by most laboratories because of contain-
ment concerns. The Karber method was used to determine the
serial dilution that neutralized 50% of the challenge virus. Results
were expressed as titers (1/dil). The lower limit of quantiﬁcation
for the assay was 4 (1/dil).
The primary endpoint for the primary series study was the
seroprotection rate (% of subjects with anti-polio antibody titer
8 (1/dil)) 1 month after primary series, with secondary
endpoints being the geometric mean titer (GMT) for anti-polio
1, 2, and 3 in each group. In addition, as a post-hoc analysis to
make the results of this study comparable with the two WHO-
sponsored studies, the seroconversion rates were estimated
descriptively for both the primary series and booster vaccina-
tions. Seroconversion was deﬁned as a 4-fold increase in post-
primary series antibody titers over the expected titer at that
time, calculated taking into account the decline of maternally
derived antibodies measured in the pre-primary series sample.
An anti-polio antibody half-life of 28 days was assumed.25 The
endpoints for the booster phase were similar to those used in
the primary series study.
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All participants were included in the evaluation of reactogeni-
city and safety. After each vaccination, participants were observed
for 30 min to monitor immediate events; their relationship to the
vaccination was assessed by the Investigator. For the following 7
days, the participant’s parent(s)/legal guardian recorded the start,
end, and intensity of pre-deﬁned (solicited) injection site reactions
(tenderness, erythema, and swelling) and solicited systemic
reactions (fever, vomiting, abnormal crying, drowsiness, loss of
appetite, and irritability) on diary cards, daily. Unsolicited events
observed during the period between the time of injection and the
next visit were also recorded by the parent(s)/guardian using the
diary card; unsolicited systemic events were assessed by the
Investigator for their relationship to the vaccination, whereas
unsolicited injection site events were considered as related to the
IPV vaccine. Serious adverse events were collected throughout the
study.
2.5. Statistical analysis
The sample size calculation was based on the non-inferiority
hypothesis of primary series immunogenicity and performed using
the Farrington and Manning formula26 to give the study a global
power of >90% with a clinically acceptable limit for non-inferiority
of 5%. Based on this, 236 infants (118 per group) were enrolled. For
each polio type, non-inferiority was demonstrated if the 95% CI of
the difference in the seroprotection rates between the ID fractional
dose group and the IM full dose group lay entirely above the
clinically acceptable limit for non-inferiority (5%) (one-sided test,
alpha = 2.5%). The 95% CI was calculated based on the Wilson score
method without continuity correction, as described by New-
combe.27 Seroprotection rates, GMTs, and seroconversion rates
were calculated with their 95% CI. For the safety evaluation, the
percentage and 95% CI of participants was calculated for each
solicited adverse event.
3. Results
3.1. Demographics
Between February and July 2008, a total of 118 participants
were enrolled in the primary series vaccination study in each
group. Of these, 115 participants in each group completed the
study. Overall participant disposition is presented in Figure 1.
Participant withdrawal was voluntary, except for one case of non-
compliance. The age of participants in both groups was similar
(mean of 45.5 days at inclusion in both groups); males and females
were equally split in the ID fractional dose group, while the IM full
dose group had more females than males (63% vs. 37%), although
this was not considered to be of clinical importance.
The booster study was conducted between April and July 2009.
Of 225 participants who returned for the booster vaccination, 113
from the ID fractional dose group and 111 from the IM full dose
group completed the booster phase, with one voluntary with-
drawal from the latter group.
3.2. Immunogenicity
3.2.1. Primary series vaccination
The non-inferiority analysis for the primary series is presented
in Table 1, and parameters for assessment of immunogenicity –
seroprotection, GMTs, and seroconversion for anti-polio 1, 2, and
3 – are presented in Table 2. The pre-primary series seroprotection
rates were 56–60%, 69–72%, and 41–45% for polioviruses 1, 2,
and 3, respectively, in both groups. Following primary seriesvaccination, seroprotection was achieved in 100% of participants
for anti-polio 1 and 2 antibodies, and in 99.1% of participants for
anti-polio 3 antibodies in the group receiving the ID fractional dose
of IPV. The seroprotection rate against all three polio types was
100% in the group receiving the IM full dose of IPV. For each polio
type, the 95% CI of the difference between the two groups lay above
the clinically acceptable limit of 5%, demonstrating the non-
inferiority of fractional dosing by the ID route in terms of
immunogenicity.
The GMTs for anti-polio 1, 2, and 3 increased in both groups
following the primary series vaccination, and were approximately
two-fold higher in the IM full dose group (Figure 2), but no formal
statistical test was performed. Seroconversion, after adjustment
for maternal antibody decay, was similarly high in the two groups:
99.1%, 94.5%, and 95.4% in the ID fractional dose group
seroconverted and 98.2%, 98.2%, and 100% in the IM full dose
group seroconverted against poliovirus 1, 2, and 3, respectively.
3.2.2. Booster vaccination
The GMTs were lower in both groups at 12–15 months than the
post-primary series levels (Figure 2). However, seroprotective
antibody titers (8 (1/dil)) against poliovirus 1, 2, and 3 were
observed in 95.5%, 95.5%, and 88.3% of the participants in the ID
fractional dose group and 100%, 98.2%, and 96.4% in the IM full dose
group.
Following booster vaccination, GMTs for anti-polio 1, 2, and 3
increased considerably in both groups, displaying an anamnestic
response to the previously administered IPV (Figure 2). Post
booster, seroprotection rates were 100% against each polio type,
including those participants whose antibody titers after the
primary series or at pre-booster were below seroprotective levels.
3.3. Safety
Solicited injection site and systemic reactions are presented in
Table 3 for the primary series and booster vaccinations. No adverse
event in either study led to discontinuation, and no deaths were
reported in either study.
3.3.1. Primary series vaccination
The incidence of at least one solicited reaction (in terms of the
number of participants experiencing a reaction) was 89.8% in the
ID fractional dose group and 77.7% in the IM full dose group.
Solicited injection site reactions were more frequent among
participants in the ID fractional dose group than in those in the IM
full dose group (83.1% vs. 59.8%). Unsolicited events were reported
in 71.2% of the participants in the ID fractional dose group and
75.2% of those in the IM full dose group; these were mostly
systemic, the most common being pyrexia (in 7.6% and 6.8% of
participants in the ID fractional dose and the IM full dose groups,
respectively). Three participants in the ID fractional dose group
and one participant in the IM full dose group had an unsolicited
injection site reaction that the Investigator assessed as related to
the vaccination (hematoma in the ID fractional dose group and
induration in the IM full dose group). There were two episodes of
gastroenteritis that were reported as serious adverse events in the
ID fractional dose group (neither was considered by the
Investigator to be related to the study vaccine or procedures)
and none in the IM full dose group.
3.3.2. Booster vaccination
The incidence of at least one solicited reaction was 54.5% in the
ID fractional dose group and 42.5% in the IM full dose group. As for
the primary vaccination, solicited injection site reactions were
more frequent among participants in the ID fractional dose group
(49.1%) compared with those in the IM full dose group (30.1%).
Figure 1. Disposition of participants in the primary and booster vaccination studies (IPV, inactivated polio vaccine; ID, intradermal; IM, intramuscular; FAS, full analysis set,
participants who received at least one dose of IPV; PP, per-protocol, participants who completed the study without any protocol violation; SAS, safety analysis set, participants
who received at least one dose of IPV and for whom safety data were collected).
Table 1
Non-inferiority analysis for primary vaccination series seroprotection data
Vaccination response (SP) ID fractional dose
(n = 109), % (95% CI)
IM full dose
(n = 114), % (95% CI)
ID fractional dose  IM full dose,
difference (95% CI)
Anti-polio 1, 8 (1/dil) 100.0 (96.7; 100.0) 100.0 (96.8; 100.0) 0.00 (3.40; 3.26)
Anti-polio 2, 8 (1/dil) 100.0 (96.7; 100.0) 100.0 (96.8; 100.0) 0.00 (3.40; 3.26)
Anti-polio 3, 8 (1/dil) 99.1 (95.0; 100.0) 100.0 (96.8; 100.0) 0.92 (5.01; 2.43)
SP, seroprotection; ID, intradermal; IM, intramuscular; CI, conﬁdence interval.
Non-inferiority was demonstrated when the 95% conﬁdence interval of the group difference lay entirely above the clinically acceptable limit for non-inferiority (5%).
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Table 2
Seroprotection, geometricmean titers, and seroconversion of anti-polio antibodies in the per-protocol analysis set, before and 1month after injectionwith inactivated polio vaccine for the primary series and the booster vaccination
ID fractional dose IM full dose
Primary series Booster Primary series Booster
Pre-primary Post-primary Pre-booster Post-booster Pre-primary Post-primary Pre-booster Post-booster
Anti-polio 1
8 (1/dil) % 59.6 (49.8; 68.9) 100.0 (96.7; 100.0) 95.5 (89.8; 98.5) 100.0 (96.7; 100.0) 56.1 (46.5; 65.4) 100.0 (96.8; 100.0) 100.0 (96.7; 100.0) 100.0 (96.7; 100.0)
GMT 10.4 (8.0; 13.4) 221 (188; 259) 48.2 (38.7; 59.9) 2833 (2392; 3356) 11.7 (8.9; 15.4) 585 (482; 710) 109.8 (84.3; 143.2) 6666 (5613; 7916)
SC % 99.1a (95.0; 100.0) 95.5 (89.8; 98.5) 98.2a (93.8; 99.8) 96.4 (91.0; 99.0)
Anti-polio 2
8 (1/dil) % 71.6 (62.1; 79.8) 100.0 (96.7; 100.0) 95.5 (89.8; 98.5) 100.0 (96.7; 100.0) 69.3 (60.0; 77.6) 100.0 (96.8; 100.0) 98.2 (93.6; 99.8) 100.0 (96.7; 100.0)
GMT 16.5 (12.9; 21.1) 234 (186; 294) 94.0 (65.8; 134.2) 3210 (2672; 3857) 16.7 (12.8; 21.6) 795 (638; 992) 132.5 (98.4; 178.3) 6522 (5540; 7678)
SC % 94.5a (88.4; 98.0) 83.8 (75.6; 90.1) 98.2a (93.8; 99.8) 88.3 (80.8; 93.6)
Anti-polio 3
8 (1/dil) % 45.0 (35.4; 54.8) 99.1 (95.0; 100.0) 88.3 (80.8; 93.6) 100.0 (96.7; 100.0) 41.2 (32.1; 50.8) 100.0 (96.8; 100.0) 96.4 (91.0; 97.0) 100.0 (96.7; 100.0)
GMT 7.8 (6.0; 10.0) 194 (157; 240) 50.3 (37.6; 67.4) 4498 (3608; 5607) 6.7 (5.2; 8.6) 774 (622; 963) 136 (103; 181) 11 952 (10 046; 14 220)
SC % 95.4a (89.6; 98.5) 94.6 (88.6; 98.0) 100.0a (96.8; 100.0) 94.6 (88.6; 98.0)
ID, intradermal; IM, intramuscular; GMT, geometric mean of titers; SC, seroconversion.
Numbers in brackets are 95% CI.
a Calculated after adjustment of individual pre-primary series antibody titers to account for maternal antibody decay.
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Table 3
Incidence of solicited injection site and systemic reactions within 8 days following vaccine injection during the primary series and the booster stage in the safety analysis set
Primary vaccination Booster
ID fractional dose IM full dose ID fractional dose IM full dose
% (n) % (n) % (n) % (n)
Solicited injection site reactions
Tenderness 60.2 (71) 50.4 (59) 28.6 (32) 21.2 (24)
Erythema 69.5 (82) 29.1 (34) 38.4 (43) 11.5 (13)
Swelling 21.2 (25) 9.4 (11) 8.9 (10) 1.8 (2)
Solicited systemic reactions
Fever 5.9 (7) 10.3 (12) 8.0 (9) 15.0 (17)
Vomiting 15.3 (18) 21.4 (25) 3.6 (4) 5.3 (6)
Crying abnormal 33.9 (40) 30.8 (36) 2.7 (3) 3.5 (4)
Drowsiness 37.3 (44) 35.0 (41) 5.4 (6) 8.0 (9)
Appetite lost 16.1 (19) 19.7 (23) 8.0 (9) 7.1 (8)
Irritability 49.2 (58) 43.6 (51) 6.3 (7) 9.7 (11)
ID, intradermal; IM, intramuscular.
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polio antigen in these historical IPV vaccines, these results have a
limited consequence relative to the current situation. Following
the (re-)development and licensure of the modern IPV during the
mid-1980s, three small-scale proof-of-concept studies carried out
in the 1990s in India did establish that a fractional dose of IPV that
had a deﬁned antigen content for polio 1, 2, and 3, administered ID
by the Mantoux technique, was immunogenic. An inherent
drawback of these studies was the lack of a control group of
study subjects receiving a full dose by IM route.18–20 Our study,
through its randomized controlled design, conﬁrms the immuno-
genic potential of a fractional dose of IPV administered ID via the
Mantoux technique and establishes beyond doubt the medical
validity of the concept.
Our data on fractional dosing for primary series polio
vaccination add to those from the WHO studies in Oman and
Cuba.22,23 However there are several differences between our
study and the two sponsored by the WHO that should be taken into
account. First are the endpoint used for non-inferiority demon-
stration and the non-inferiority criteria deﬁnitions. The WHO
studies compared the seroconversion rates (deﬁned as the % of
subjects with a 4-fold increase over adjusted pre-vaccination
titers) using the overlap of the 95% CI of the observed
seroconversion rates, while we compared the seroprotection rates
(deﬁned as the % of subjects with antibody titers 8 (1/dil), and
known to be inﬂuenced by maternally derived antibodies that
could still be present at that time) by testing the lower limit of the
95% CI between the observed seroprotection rates using a non-
inferiority limit of 5%. Second, and perhaps more importantly, is
the type of serological assay used in the studies. The assay used in
the WHO studies was based on the Sabin strains, whereas our assay
was based on wild-type Salk strains. Sabin strains are antigenically
different to Salk strains, particularly in terms of the antigenic sites
responsible for the induction of the neutralizing antibodies,
thereby potentially affecting the overall levels detected.28 Fur-
thermore, assay performance is also dependent on factors such as
the type of cells (HEp-2 or Vero) used to grow the target virus, the
size of the viral inoculum, the duration and temperature of the
serum–virus interaction before cell culture, and the number of
serial dilutions of the tested sera.29,30 The type of assay (cytopathic
effect or micro-metabolic inhibition test) can also inﬂuence the
assay results. Despite numerous attempts to standardize the assay,
the evaluation of the effect of the viral strain relative to other
variables has never been thoroughly described particularly for the
evaluation of neutralizing antibodies induced by IPV, and there is
still no widely established international standard assay.31 More-
over, unpublished data from Sanoﬁ Pasteur indicate that the use of
Sabin strains for the seroneutralization assay results in asigniﬁcant underestimation of the antibody titers induced by
IPV, thereby possibly skewing the conclusions of the WHO-
sponsored studies. It is therefore very important to consider the
characteristics of the assay used when comparing immunogenicity
data between trials.
In our study, the seroconversion rates observed in the context of
a relatively high prevalence of maternal antibodies was quite high
(>94.5%) for each poliovirus type, and the post-primary antibody
levels cannot be accounted for solely by the pre-primary series
maternally-derived antibodies (56–60%, 69–72%, and 41–45% for
polioviruses type 1, 2, and 3, respectively). The prevalence of
maternally derived antibodies was higher in the Cuban study (83–
88%, 85–91%, and 40–44% for polioviruses type 1, 2, and 3,
respectively) than in the present study.
Finally, the WHO studies reported overall responses in terms of
median titer (with an assay based on dilution range of samples
ending at 1024); this is known to overestimate the results
compared to a geometric estimation of the means. Also, the
median titers were calculated only from seroconverted individuals,
further complicating the comparison of the titers between studies.
It is nevertheless true that the overall immunogenicity of the ID
fractional dose is lower than the IM full dose, as evidenced by the
lower mean titers in the ID fractional dose group. This creates
doubt regarding the persistence of good immunological memory,
and so brings into question the duration of protection afforded by
the use of a fractional dose of IPV. We consider, however, that this
should not be used as an argument against the medical validity of
the concept. Good antibody persistence until 4–5 years of age has
been shown after a three-dose primary series without a booster
during the second year of life.32,33
While our study reinforces previous observations and proves
the medical validity of fractional dose IPV administered ID, the
question remains whether a DSJI can be developed, manufactured,
and affordably deployed for mass vaccination, as the mass usage of
needle ID injections is not foreseeable. Further evaluation will be
needed to translate the concept of fractional dosing of IPV by ID
route into a more cost-effective strategy in the ongoing campaign
for polio eradication in low-income nations.
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